HCYTA-60K
MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A
Configurable Human Cytokine/Chemokine/Growth Factor 48-Plex Panel A
别名:
Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel
登录 查看组织和合同定价。
关于此项目
NACRES:
NA.84
UNSPSC Code:
12161503
Quality Level
species reactivity
human
packaging
pkg of 1 ea
manufacturer/tradename
Milliplex®
technique(s)
multiplexing: suitable
input
plasma
serum
cell culture supernatant(s)
detection method
fluorometric (Luminex® xMAP® technology)
shipped in
wet ice
storage temp.
2-8°C
General description
Cytokines, chemokines, and growth factors are key mediatorsof immune system functions capable of signaling through autocrine, paracrine,and endocrine mechanisms. Their pleiotropic immunomodulatory propertiesallow these biomolecules to react to diverse stimuli and regulate the immuneresponse, either promoting or inhibiting inflammation.
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 48 analytes in human serum, plasma, and cell culture supernatants.
Analytes included: sCD40L, EGF, Eotaxin/CCL11, FGF-2/FGF-basic, FLT-3L, Fractalkine/CX3CL1, G-CSF, GM-CSF, GROα, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A/CTLA8, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10/CXCL10, MCP-1/CCL2, MCP-3/CCL7, M-CSF, MDC, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AA, PDGF-AB/BB, RANTES/CCL5, TGFα, TNFα, TNFβ/LTA, VEGF-A
Note: RANTES cannot be plexed with other cytokines in this panel due to a required 1:100 dilution of plasma/serum samples.
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Analytes included: sCD40L, EGF, Eotaxin/CCL11, FGF-2/FGF-basic, FLT-3L, Fractalkine/CX3CL1, G-CSF, GM-CSF, GROα, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A/CTLA8, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10/CXCL10, MCP-1/CCL2, MCP-3/CCL7, M-CSF, MDC, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AA, PDGF-AB/BB, RANTES/CCL5, TGFα, TNFα, TNFβ/LTA, VEGF-A
Note: RANTES cannot be plexed with other cytokines in this panel due to a required 1:100 dilution of plasma/serum samples.
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Features and Benefits
- 48-Plex Power, Simplified: One kit unlocks 48 biomarkers—replaces multiple ELISAs and slashes costs.
- More Than 20-Year Multiplexing Legacy: The original multiplex innovator—trusted by top pharma companies for critical assays.
- Cancer, Autoimmunity, & Beyond: Power research in immunotherapy, sepsis, Alzheimer’s, and Long COVID biomarker discovery.
- Intuitive Workflow: User-friendly protocols that require minimal training, allowing researchers to achieve publication-ready results without extensive background in multiplex assays.
- Configurable Assay Design: Configure your panel by selecting specific analytes based on your research needs, allowing for a tailored approach that maximizes relevance and impact.
- Robust Sample Compatibility: Verified for serum, plasma, PBMC supernatants, and cell/tissue lysates. Tested across normal and disease-state samples for broad applicability.
- Peer-Reviewed Credibility: Frequently cited in immunology and clinical research publications. Trusted by academic institutions, CROs, and pharma companies.
- Performance Highlights from Comparative Studies: MILLIPLEX® assays showed highest reproducibility among Luminex®-based kits in a head-to-head study and in disease profiling (e.g., ovarian cancer, sepsis), and MILLIPLEX® assays detected more significantly elevated analytes than competitors.
- Global Support & Documentation: Backed by extensive technical documentation, protocols, and customer support.
Legal Information
Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
For research use only. Not for use in diagnostic procedures.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
target_organs
Respiratory Tract
存储类别
10 - Combustible liquids
wgk
WGK 3
法规信息
新产品
此项目有
相关内容
通过适合的免疫检测产品，探索神经免疫和神经炎症细胞因子及神经退行性疾病生物标志物。
Cytokine multiplex assays allow researchers to easily investigate the immune system. The MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Multiplex Panels A and B are multiplex assays for cytokine detection that each offer a unique combination of 48 analytes that can be simultaneously analyzed in a small sample volume.
Immunology multiplex assays, like MILLIPLEX® assays, allow researchers to investigate more immune biomarkers simultaneously, saving time and resources.
Liam J O'Neil et al.
Frontiers in immunology, 13, 958145-958145 (2022-09-27)
The development of autoantibody directed towards citrullinated proteins (ACPA) are predictive of RA in at-risk individuals. The biological events that underpin loss of immune tolerance and progression into inflammatory arthritis are not known. We sought to identify serum proteomic alterations
Qi Wang et al.
Frontiers in immunology, 13, 995223-995223 (2022-09-27)
In primary biliary cholangitis (PBC), the levels of serum IL-2 were involved in liver inflammation and immune changes. This study aimed to investigate the prognostic significance of serum IL-2 combined with total bilirubin (TBIL) in liver failure and cytokine changes
Myung-Ho Kim et al.
The Journal of infectious diseases (2021-05-27)
We analyzed the plasma levels of interferons and cytokines, and the expression of interferon-stimulated genes in peripheral blood mononuclear cells in COVID-19 patients with different disease severity. Mild patients exhibited transient type I interferon responses, while ICU patients had prolonged